Lung cancer remains the leading cause of cancer-related mortality worldwide, underscoring the urgent need for improved therapeutic strategies grounded in ...
ATCC and the Broad Institute report the development of engineered isogenic cancer models designed to replicate resistance to targeted therapies, beginning with osimertinib, the latest-generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results